Latest news with #GeneralRegulation
Business Wire
24-06-2025
- Business
- Business Wire
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB 1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16 th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Company's website at: *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB 1 receptor of the endocannabinoid system (CB 1 -SSi). CB 1 -SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB 1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB 1 -SSi appear to selectively inhibit the disease-related activity of the CB 1 receptor without disrupting its normal physiological activity. CB 1 -SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases. Aelis Farma currently has two first-in-class clinical-stage drug candidates. AEF0117 for the treatment of cannabis use disorders (CUD), that has shown to be able to decrease cannabis use across two studies. AEF0217 for cognitive disorders, which has shown in a Phase 1/2 to be safe and able to improve adaptive behaviour in young adults with Down syndrome (Trisomy 21). The clinical results obtained with these 2 molecules have confirmed the pharmacological activity of CB 1 -SSi in humans. The Company also has a portfolio of new innovative CB 1 -SSi for the treatment of other disorders associated with a dysregulation of the activity of the CB 1 receptor, including diseases involving peripheral organs, such as obesity and related metabolic conditions. The different drugs developed by the company belong to the same general pharmacological class, the CB 1 -SSi, but have distinct functional effects allowing to target different types of dysregulations of the CB 1 receptor and guaranteeing that the different compounds are not substitutable one with the others. Aelis Farma draws on the talents of more than 25 highly qualified employees. For more information, visit and follow us on LinkedIn and Twitter. ISIN: FR0014007ZB4 Ticker: AELIS C Compartment of Euronext Paris Disclaimer Forward-looking statements Some information contained in this press release is forward-looking statements, not historical data. These forward-looking statements are based on current beliefs, expectations, and assumptions, including, but not limited to, assumptions about Aelis Farma's current and future strategy and the environment in which Aelis Farma operates. They involve known and unknown risks, uncertainties, and other factors, which may cause actual results, performance, achievements, or industry results or other events, to differ materially from those described or implied by such forward-looking statements. These risks and uncertainties include those set out and described in detail in Chapter 3 "Risk Factors" of Aelis Farma's Universal Registration Document filed with the Autorité des Marchés Financiers on April 28, 2025, under number D.25-0314. These forward-looking statements are made only as of the date of this press release and Aelis Farma expressly disclaims any obligation or undertaking to release any updates or corrections to the forward-looking statements included in this press release to reflect any change in expectations or events, conditions, or circumstances on which any such forward-looking statement is based. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Aelis Farma's control. Actual results could differ materially from those described in, or implied or projected by, forward-looking information and statements.
Yahoo
17-06-2025
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDF
Yahoo
17-06-2025
- Business
- Yahoo
QUADIENT SA: Availability of the share buyback program description
Paris, June 17, 2025 Quadient (Euronext Paris: QDT) announces the availability of the description of its share buyback program, launched by the Board of Directors on June 13, 2025, following the authorization granted by the Ordinary General Meeting held on June 13, 2025 (17th resolution). This description has been prepared in compliance with the provisions of Articles 241-1 et seq. of the General Regulation of the Autorité des Marchés Financiers (AMF), Articles L. 22-10-62 et seq. of the French Commercial Code, as well as the provisions of European Regulation No. 596/2014 and Delegated Regulation No. 2016/1052. This document can be consulted on the Company's investor relations website ( For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 Or visit our website: Attachment PDFError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-06-2025
- Business
- Yahoo
Ipsen - May 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 May 2025 83,814,526 Gross total* of voting rights: 132,084,744 Net total** of voting rights: 131,256,780 (1) Existence of a statutory clause imposing an obligation to declare threshold crossing complementary to the one relative to the legal thresholds (Article 10). * Gross total = total number of voting rights attached to the total number of shares, including the number of shares which benefit of double voting rights and the number of treasury shares. The « Gross total » is used as a basis for the calculation of threshold crossings. ** Net total = total number of voting rights attached to the total number of shares – shares without voting rights. ** Net total = total number of voting rights attached to the total number of shares – shares without voting rights. Attachment Declaration relative to the total number of voting rights - May 2025
Yahoo
12-06-2025
- Business
- Yahoo
Number of Shares and Voting Rights of ADOCIA as of May 31st, 2025
LYON, France, June 12, 2025--(BUSINESS WIRE)--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French "Code de Commerce" and article 223-16 of the General Regulation of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF"), ADOCIA SA (Paris:ADOC), a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of May 31st, 2025. Month Date Total number of outstanding shares Total number of theoretical voting rights (1) Total number of exercisable voting rights (2) May 05/31/2025 18,087,690 20,213,633 20,168,948 (1) The total number of theoretical voting rights is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. (2) The total number of exercisable voting rights is calculated without taking into account the shares with suspended voting rights, in this case, shares held by the Company in the context of a liquidity agreement. It is provided for the information of the public, in accordance with the AMF recommendation of July 17, 2007. About Adocia Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity. The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform. Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241). View source version on Contacts Adocia Olivier Soula CEOcontactinvestisseurs@ Tel: +33 4 72 610 Ulysse Communication Adocia Media and Investor Relations Bruno ArabianNicolas Entzadocia@ + 33 (0)6 87 88 47 26 Sign in to access your portfolio
